Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 B, Expanding U.S. Rare-Disease Portfolio

Angelini Pharma announced Thursday it will purchase Catalyst Pharmaceuticals, a Florida‑based company focused on rare‑disease medicines, for about $4.1 billion in cash.

The transaction values Catalyst at $31.50 per share, representing a 28 % premium to the average share price in the 30 days before the deal became public on April 22.

The acquisition gives Angelini a foothold in the United States and adds Catalyst’s three approved drugs to its neurology and rare‑disease pipeline.

The move aligns with Angelini’s strategy to broaden its presence in the U.S. market and strengthen its portfolio in neurology and rare diseases.